about
Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets.Incorporating observational data into the formulary decision-making process--summary of a roundtable discussion.Systematic review on quality control for drug management programs: is quality reported in the literature?Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.Systematic analysis of outcomes evaluations applied to drug management programs.Need for multicriteria evaluation of generic drug policies.Health economic evaluation of Gd-EOB-DTPA MRI vs ECCM-MRI and multi-detector computed tomography in patients with suspected hepatocellular carcinoma in Thailand and South Korea.Health economic assessment of Gd-EOB-DTPA MRI versus ECCM-MRI and multi-detector CT for diagnosis of hepatocellular carcinoma in China.EVALUATION OF PATIENT AND PUBLIC INVOLVEMENT INITIATIVES IN HEALTH TECHNOLOGY ASSESSMENT: A SURVEY OF INTERNATIONAL AGENCIES.Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.Patient Preference Studies During Early Drug Development: Aligning Stakeholders to Ensure Development Plans Meet Patient NeedsStakeholder driven development of a multi-criteria decision analysis tool for purchasing off-patent pharmaceuticals in KuwaitRelative efficacy of melatonin and 5-methoxytryptamine in terms of their antigonadotrophic and counterantigonadotrophic actions in male Syrian hamsters[Swiss Tissue Culture Society]Are Patient Reported Outcomes Relevant To Patients? Learnings From A Patient Advocate SurveyShaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare CoverageExternal Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage
P50
Q30834906-41E3FB16-E77A-47D5-8476-FC795906C279Q31153721-2206FA67-57D5-457E-9357-BAD660EE2F29Q33412577-AD5C8A98-BB84-4DC4-B0AC-7D9A77BAAAA8Q33730376-FBD894DE-2BC7-4BEF-9C16-9E03F49C9FC4Q37320040-DF5FE2A7-3106-466B-8F61-CD2CE56B001FQ38379232-343CEA2B-1B69-43B9-95D4-F97B42607EA1Q39879349-2AF3EE54-B02E-49E0-A4D8-A6B37417C795Q48259378-D23CCA44-F4DB-4820-9806-0FD1EB3F4C67Q48558647-D1BB8168-BA40-4D89-9296-133DE0F16793Q53119134-3B4A701E-C90E-4161-BFA5-E7E0FB489F6FQ64093281-B980551D-5D22-4D7C-AF48-6000BB03FD5DQ64109540-9CAC3487-7F89-41F2-AEC9-F2BD79392BC4Q70979625-E3BB149B-5CAA-43A3-A284-005A1E2DEBB5Q73440544-B9C734F8-FCC4-43D0-AA2A-C7B1DF65808BQ89241466-D1B82188-E6B8-467A-B2D0-826DEECED603Q89484291-812EA2AE-3B72-4170-9D52-749327DC669AQ92640951-1FC8908C-1D08-4B20-8937-CA3DBB553C14
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Anke-Peggy Holtorf
@ast
Anke-Peggy Holtorf
@en
Anke-Peggy Holtorf
@es
Anke-Peggy Holtorf
@nl
Anke-Peggy Holtorf
@sl
type
label
Anke-Peggy Holtorf
@ast
Anke-Peggy Holtorf
@en
Anke-Peggy Holtorf
@es
Anke-Peggy Holtorf
@nl
Anke-Peggy Holtorf
@sl
prefLabel
Anke-Peggy Holtorf
@ast
Anke-Peggy Holtorf
@en
Anke-Peggy Holtorf
@es
Anke-Peggy Holtorf
@nl
Anke-Peggy Holtorf
@sl
P106
P31
P496
0000-0002-4638-5351